These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2670428)

  • 41. Effect of erythropoietin therapy on the red cell volume of uraemic and non-uraemic rats.
    Anagnostou A; Barone J; Kedo A; Fried W
    Br J Haematol; 1977 Sep; 37(1):85-91. PubMed ID: 588481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Erythropoietin: the developing story.
    Cotes PM
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):805-6. PubMed ID: 3130919
    [No Abstract]   [Full Text] [Related]  

  • 43. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 45. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 46. Is the use of subcutaneous epoetin beta once a week really equivalent to a more frequent administration of the same total dose?
    Andrulli S; D'Amico M; Locatelli F
    Nephrol Dial Transplant; 2001 Dec; 16(12):2439-40. PubMed ID: 11733645
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment.
    Wiecek A; Kokot F; Marcinkowski W
    Nephron; 1995; 69(4):489-90. PubMed ID: 7777122
    [No Abstract]   [Full Text] [Related]  

  • 48. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
    Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
    Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uraemic pericarditis: a reversible inflammatory state of resistance to recombinant human erythropoietin in haemodialysis patients.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1997 May; 12(5):1051-4. PubMed ID: 9175071
    [No Abstract]   [Full Text] [Related]  

  • 50. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
    Savica V; Costantino G; Monardo P; Bellinghieri G
    Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stable renal function and benign course in azotemic diabetics treated with erythropoietin for one year.
    Brown CD; Friedman EA
    Contrib Nephrol; 1991; 88():182-9; discussion 190-1. PubMed ID: 2040181
    [No Abstract]   [Full Text] [Related]  

  • 52. [Improving the administration of erythropoietin].
    Suszko P; Rousseau S; Poite O
    Soins; 2007 Oct; (719 Suppl):S22-3. PubMed ID: 18050874
    [No Abstract]   [Full Text] [Related]  

  • 53. [Hematologic changes in chronic uremia].
    Schnurr E
    Dtsch Med Wochenschr; 1979 Nov; 104(47):1678-82. PubMed ID: 510197
    [No Abstract]   [Full Text] [Related]  

  • 54. [Recent findings on the pathogenesis and therapy of anemia in chronic kidney failure].
    Moccia F; Morra L; Gurreri G
    Recenti Prog Med; 1992 Oct; 83(10):572-6. PubMed ID: 1462041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How erythropoietin affects bone marrow of uremic patients.
    Sikole A; Stojanovic A; Polenakovic M; Petrusevska G; Sadikario S; Saso R; Jovanovski M
    Am J Nephrol; 1997; 17(2):128-36. PubMed ID: 9096443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 57. Effect of erythropoietin administration on thyroid functions of the patients undergoing regular hemodialysis.
    Seyrek N; Paydas S; Sagliker Y
    Nephron; 1996; 72(4):714-5. PubMed ID: 8730452
    [No Abstract]   [Full Text] [Related]  

  • 58. Erythropoietin and its clinical promise.
    Erslev AJ; Schuster SJ; Caro J
    Eur J Haematol; 1989 Nov; 43(5):367-73. PubMed ID: 2693128
    [No Abstract]   [Full Text] [Related]  

  • 59. [Iron poisoning as a risk in the treatment of nephrogenic anemia].
    Hansen BL; Pedersen FB
    Ugeskr Laeger; 1985 Aug; 147(35):2747-9. PubMed ID: 4071711
    [No Abstract]   [Full Text] [Related]  

  • 60. [Quinbolone in the therapy of anemia in uremic patients during periodic hemodialytic treatment].
    Amato M; Bigioli F; Beconi D; Martinelli F; Lapini V; Salvadori M
    Clin Ter; 1980 Jul; 94(1):57-65. PubMed ID: 7438723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.